ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "cc44ca00-c8f5-4134-aae1-9c1fa09174b8"}, "_deposit": {"id": "11481", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "11481"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00011481"}, "item_7_alternative_title_1": {"attribute_name": "\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_alternative_title": "Current Treatment for CML-imatinib: The Tyrosine Kinase Inhibitor Targeting Bcr-Abl Oncoprotein(Molecular Targeted Therapy for Cancer)"}]}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2007-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "611", "bibliographicPageStart": "601", "bibliographicVolumeNumber": "121", "bibliographic_titles": [{"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c"}, {"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "The history of treatments for chronic myelogenous leukemia (CML) represents a success story caused by the development of molecular medicine. Imatinib myslate (Glivec), a tyrosine kinase inhibitor targeting the Bcr-Abl oncoprotein, which is associated with the pathogenesis of CML and the most specific marker of CML, has induced not only hematological and cytogenetic remissions but surprising genetic response in the patients of CML in all phases. In this report we present the mechanism of action of imatinib, detection methods of Ph clone used for the evaluation of the effects of imatinib treatment, clinical results of imatinib therapy in Niigata Glivec Study Group, future problems and novel kinase inhibitors nilotinib and dasatinib. Stern cell transplantation remains to be a useful option for getting into the level of complete genetic cure although it has been not generally used as first-line treatment already. Within several years many treatment methods will be available for patients with CML, so standardizes and quantitative methods have to be arranged to clarify the effectiveness of targeting therapy.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "\u8457\u8005\u5225\u540d", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "77979", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Narita, Miwako"}]}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u65b0\u6f5f\u533b\u5b66\u4f1a"}]}, "item_7_relation_31": {"attribute_name": "\u7570\u7248\u3067\u3042\u308b", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://ci.nii.ac.jp/naid/110007146174", "subitem_relation_type_select": "URI"}}]}, "item_7_rights_15": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "\u672c\u6587\u30c7\u30fc\u30bf\u306f\u5b66\u5354\u4f1a\u306e\u8a31\u8afe\u306b\u57fa\u3065\u304dCiNii\u304b\u3089\u8907\u88fd\u3057\u305f\u3082\u306e\u3067\u3042\u308b"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u6210\u7530, \u7f8e\u548c\u5b50"}], "nameIdentifiers": [{"nameIdentifier": "77978", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "110007146174.pdf", "filesize": [{"value": "1.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1100000.0, "url": {"label": "110007146174.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/11481/files/110007146174.pdf"}, "version_id": "876c6edd-6d4c-4d12-92d0-9cd1e8149cfb"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "2 \u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306b\u5bfe\u3059\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u6cbb\u7642(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u304c\u3093\u306e\u5206\u5b50\u6a19\u7684\u6cbb\u7642, \u7b2c628\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "2 \u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306b\u5bfe\u3059\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u6cbb\u7642(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u304c\u3093\u306e\u5206\u5b50\u6a19\u7684\u6cbb\u7642, \u7b2c628\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)"}, {"subitem_title": "2 \u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306b\u5bfe\u3059\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u6cbb\u7642(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u304c\u3093\u306e\u5206\u5b50\u6a19\u7684\u6cbb\u7642, \u7b2c628\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/538/997"], "permalink_uri": "http://hdl.handle.net/10191/32852", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2015-08-07"}, "publish_date": "2015-08-07", "publish_status": "0", "recid": "11481", "relation": {}, "relation_version_is_last": true, "title": ["2 \u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306b\u5bfe\u3059\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u6cbb\u7642(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u304c\u3093\u306e\u5206\u5b50\u6a19\u7684\u6cbb\u7642, \u7b2c628\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a)"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 03 紀要論文
  1. 250 大学院医歯学総合研究科(医)
  2. 20 紀要
  3. 02 新潟医学会雑誌
  4. 第121巻第11号

2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)

http://hdl.handle.net/10191/32852
51970cdb-d6b0-442c-8bc0-de0c06f7dc48
名前 / ファイル ライセンス アクション
110007146174.pdf 110007146174.pdf (1.1 MB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2015-08-07
タイトル
タイトル 2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)
タイトル
言語 en
タイトル 2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)
言語
言語 jpn
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
その他のタイトル
その他のタイトル Current Treatment for CML-imatinib: The Tyrosine Kinase Inhibitor Targeting Bcr-Abl Oncoprotein(Molecular Targeted Therapy for Cancer)
著者 成田, 美和子

× 成田, 美和子

WEKO 77978

成田, 美和子

Search repository
著者別名
識別子
識別子 77979
識別子Scheme WEKO
姓名
姓名 Narita, Miwako
抄録
内容記述タイプ Abstract
内容記述 The history of treatments for chronic myelogenous leukemia (CML) represents a success story caused by the development of molecular medicine. Imatinib myslate (Glivec), a tyrosine kinase inhibitor targeting the Bcr-Abl oncoprotein, which is associated with the pathogenesis of CML and the most specific marker of CML, has induced not only hematological and cytogenetic remissions but surprising genetic response in the patients of CML in all phases. In this report we present the mechanism of action of imatinib, detection methods of Ph clone used for the evaluation of the effects of imatinib treatment, clinical results of imatinib therapy in Niigata Glivec Study Group, future problems and novel kinase inhibitors nilotinib and dasatinib. Stern cell transplantation remains to be a useful option for getting into the level of complete genetic cure although it has been not generally used as first-line treatment already. Within several years many treatment methods will be available for patients with CML, so standardizes and quantitative methods have to be arranged to clarify the effectiveness of targeting therapy.
書誌情報 新潟医学会雑誌
en : 新潟医学会雑誌

巻 121, 号 11, p. 601-611, 発行日 2007-11
出版者
出版者 新潟医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 00290440
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AN00182415
権利
権利情報 本文データは学協会の許諾に基づきCiNiiから複製したものである
著者版フラグ
値 publisher
異版である
関連タイプ isVersionOf
関連識別子
識別子タイプ URI
関連識別子 http://ci.nii.ac.jp/naid/110007146174
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 17:32:25.539385
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio